| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 24 | 2018 | 331 | 5.480 |
Why?
|
| Skin Neoplasms | 26 | 2025 | 411 | 5.030 |
Why?
|
| Biomarkers, Tumor | 10 | 2019 | 506 | 1.750 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 3 | 2016 | 13 | 1.440 |
Why?
|
| Serpins | 3 | 2016 | 18 | 1.440 |
Why?
|
| Nerve Growth Factors | 3 | 2016 | 27 | 1.430 |
Why?
|
| Eye Proteins | 3 | 2016 | 74 | 1.400 |
Why?
|
| MicroRNAs | 5 | 2017 | 685 | 1.380 |
Why?
|
| MART-1 Antigen | 3 | 2018 | 8 | 1.120 |
Why?
|
| SOXE Transcription Factors | 2 | 2018 | 6 | 0.920 |
Why?
|
| Hemangioma | 3 | 2011 | 28 | 0.910 |
Why?
|
| Lymphangiogenesis | 4 | 2013 | 14 | 0.880 |
Why?
|
| Lymphatic Metastasis | 4 | 2016 | 86 | 0.860 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 523 | 0.800 |
Why?
|
| Melanocytes | 4 | 2018 | 77 | 0.760 |
Why?
|
| Nevus, Pigmented | 3 | 2018 | 19 | 0.740 |
Why?
|
| Hemangioendothelioma | 3 | 2010 | 5 | 0.700 |
Why?
|
| Homeodomain Proteins | 4 | 2014 | 266 | 0.670 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 198 | 0.660 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2016 | 5 | 0.620 |
Why?
|
| Muir-Torre Syndrome | 1 | 2019 | 1 | 0.610 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 893 | 0.600 |
Why?
|
| Keratosis, Actinic | 1 | 2018 | 4 | 0.570 |
Why?
|
| Skin Diseases | 2 | 2016 | 82 | 0.550 |
Why?
|
| Up-Regulation | 3 | 2011 | 373 | 0.540 |
Why?
|
| TRPM Cation Channels | 1 | 2016 | 15 | 0.510 |
Why?
|
| Vascular Endothelial Growth Factor C | 3 | 2013 | 20 | 0.510 |
Why?
|
| Humans | 46 | 2025 | 63319 | 0.470 |
Why?
|
| Cutis Laxa | 1 | 2014 | 7 | 0.460 |
Why?
|
| Aged | 17 | 2025 | 14400 | 0.460 |
Why?
|
| Neovascularization, Pathologic | 3 | 2004 | 139 | 0.450 |
Why?
|
| Sarcoidosis | 1 | 2015 | 34 | 0.450 |
Why?
|
| Psoriasis | 1 | 2015 | 55 | 0.450 |
Why?
|
| Vulvar Neoplasms | 2 | 2011 | 11 | 0.450 |
Why?
|
| Female | 29 | 2019 | 32812 | 0.440 |
Why?
|
| Amyloidosis | 1 | 2014 | 65 | 0.430 |
Why?
|
| Nail Diseases | 1 | 2014 | 49 | 0.420 |
Why?
|
| Male | 24 | 2025 | 29840 | 0.410 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 70 | 0.410 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 5449 | 0.400 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 47 | 0.390 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2181 | 0.390 |
Why?
|
| Middle Aged | 14 | 2018 | 17562 | 0.380 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1616 | 0.380 |
Why?
|
| Carcinoma, Verrucous | 1 | 2011 | 3 | 0.360 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2008 | 41 | 0.350 |
Why?
|
| Ribonuclease III | 1 | 2011 | 87 | 0.350 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 35 | 0.350 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1146 | 0.350 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 31 | 0.340 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 200 | 0.330 |
Why?
|
| Cicatrix | 1 | 2010 | 61 | 0.330 |
Why?
|
| Lymph Nodes | 2 | 2008 | 224 | 0.330 |
Why?
|
| Transcriptome | 1 | 2013 | 388 | 0.320 |
Why?
|
| Tissue Fixation | 1 | 2009 | 20 | 0.320 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 17 | 0.320 |
Why?
|
| Formaldehyde | 1 | 2009 | 31 | 0.320 |
Why?
|
| Membrane Glycoproteins | 6 | 2011 | 668 | 0.320 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 348 | 0.310 |
Why?
|
| Oxidoreductases | 3 | 2001 | 64 | 0.310 |
Why?
|
| Child | 8 | 2018 | 4531 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 4 | 2014 | 278 | 0.300 |
Why?
|
| Microbodies | 3 | 1996 | 4 | 0.290 |
Why?
|
| Sarcoma, Kaposi | 1 | 2008 | 17 | 0.290 |
Why?
|
| Adult | 13 | 2018 | 16796 | 0.280 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 973 | 0.280 |
Why?
|
| Animals | 21 | 2017 | 20616 | 0.270 |
Why?
|
| Skin | 4 | 2017 | 373 | 0.260 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 195 | 0.260 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 1464 | 0.260 |
Why?
|
| Neoplasms | 2 | 2009 | 1361 | 0.250 |
Why?
|
| Lymphatic System | 2 | 2005 | 19 | 0.240 |
Why?
|
| Hair | 2 | 2017 | 82 | 0.240 |
Why?
|
| Child, Preschool | 6 | 2011 | 1995 | 0.240 |
Why?
|
| Mice | 15 | 2016 | 10817 | 0.230 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 17 | 0.220 |
Why?
|
| Phenotype | 3 | 2019 | 1199 | 0.220 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 49 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 517 | 0.220 |
Why?
|
| Cell Movement | 4 | 2014 | 451 | 0.220 |
Why?
|
| Dendritic Cells | 3 | 2025 | 525 | 0.220 |
Why?
|
| In Situ Hybridization | 3 | 2016 | 216 | 0.210 |
Why?
|
| Young Adult | 5 | 2018 | 4687 | 0.210 |
Why?
|
| Vesicular Transport Proteins | 4 | 2010 | 113 | 0.200 |
Why?
|
| Adolescent | 5 | 2018 | 6247 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 297 | 0.180 |
Why?
|
| Glycoproteins | 5 | 2006 | 187 | 0.180 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 488 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2011 | 257 | 0.180 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2001 | 6 | 0.180 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 19 | 0.170 |
Why?
|
| Response Elements | 1 | 2001 | 44 | 0.170 |
Why?
|
| Antigens, Ly | 1 | 2001 | 42 | 0.170 |
Why?
|
| Prostate | 1 | 2001 | 90 | 0.170 |
Why?
|
| Testosterone | 1 | 2001 | 121 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 147 | 0.160 |
Why?
|
| Hyperplasia | 2 | 2018 | 88 | 0.160 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 3 | 0.150 |
Why?
|
| Heredity | 1 | 2019 | 6 | 0.150 |
Why?
|
| Prognosis | 3 | 2013 | 1747 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2019 | 16 | 0.150 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 28 | 0.150 |
Why?
|
| Tail | 2 | 2016 | 6 | 0.150 |
Why?
|
| Pedigree | 1 | 2019 | 193 | 0.150 |
Why?
|
| Point Mutation | 1 | 2019 | 166 | 0.140 |
Why?
|
| Base Sequence | 3 | 2015 | 1329 | 0.140 |
Why?
|
| Liver | 2 | 2001 | 852 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2006 | 1537 | 0.140 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2010 | 16 | 0.140 |
Why?
|
| Fibrosarcoma | 1 | 1998 | 13 | 0.140 |
Why?
|
| Antigens, CD34 | 2 | 2010 | 56 | 0.140 |
Why?
|
| Sunlight | 1 | 2018 | 30 | 0.140 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 77 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 313 | 0.140 |
Why?
|
| Skin Abnormalities | 1 | 2017 | 8 | 0.140 |
Why?
|
| Nails, Malformed | 1 | 2017 | 6 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 771 | 0.140 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 1990 | 0.140 |
Why?
|
| Papillomaviridae | 2 | 2014 | 59 | 0.130 |
Why?
|
| Biopsy | 1 | 2019 | 444 | 0.130 |
Why?
|
| Catalase | 1 | 1996 | 23 | 0.130 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 204 | 0.130 |
Why?
|
| Biological Ontologies | 1 | 2016 | 1 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2025 | 66 | 0.130 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 263 | 0.130 |
Why?
|
| Hyperpigmentation | 1 | 2016 | 6 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2016 | 15 | 0.120 |
Why?
|
| Dermis | 2 | 2016 | 18 | 0.120 |
Why?
|
| Fibroblasts | 1 | 1998 | 387 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 3389 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 146 | 0.120 |
Why?
|
| Alopecia Areata | 1 | 2015 | 10 | 0.120 |
Why?
|
| Clobetasol | 1 | 2015 | 6 | 0.120 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 32 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 279 | 0.120 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2015 | 4 | 0.120 |
Why?
|
| Desmoplakins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2015 | 20 | 0.120 |
Why?
|
| Hair Diseases | 1 | 2015 | 6 | 0.120 |
Why?
|
| Infliximab | 1 | 2015 | 50 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 718 | 0.110 |
Why?
|
| Papilloma | 1 | 2014 | 12 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 400 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2016 | 186 | 0.110 |
Why?
|
| Blotting, Northern | 2 | 2009 | 150 | 0.110 |
Why?
|
| Acyl-CoA Oxidase | 3 | 2001 | 7 | 0.110 |
Why?
|
| Rituximab | 1 | 2015 | 87 | 0.110 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 112 | 0.110 |
Why?
|
| Rats | 5 | 2009 | 1977 | 0.110 |
Why?
|
| Sebaceous Glands | 2 | 2017 | 6 | 0.110 |
Why?
|
| Infant | 3 | 2010 | 1650 | 0.110 |
Why?
|
| Mice, Congenic | 1 | 2014 | 22 | 0.110 |
Why?
|
| Pigmentation | 1 | 2014 | 24 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 165 | 0.110 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 44 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 463 | 0.110 |
Why?
|
| Apoptosis | 2 | 2003 | 1074 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 542 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2015 | 188 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 57 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 123 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 67 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2001 | 1512 | 0.100 |
Why?
|
| Epigenomics | 1 | 2013 | 62 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 168 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2014 | 398 | 0.090 |
Why?
|
| Lymphangioma | 1 | 2011 | 3 | 0.090 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 9 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 1007 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2011 | 16 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 33 | 0.090 |
Why?
|
| Cell Proliferation | 4 | 2013 | 982 | 0.090 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2011 | 20 | 0.090 |
Why?
|
| Granuloma, Pyogenic | 1 | 2010 | 3 | 0.090 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2010 | 4 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2010 | 195 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 501 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 919 | 0.080 |
Why?
|
| Calreticulin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2010 | 275 | 0.080 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2009 | 15 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2018 | 6642 | 0.080 |
Why?
|
| Genes, Recessive | 1 | 2009 | 52 | 0.080 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cell Line | 2 | 2011 | 2038 | 0.080 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2008 | 10 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2011 | 49 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2017 | 2108 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2014 | 273 | 0.070 |
Why?
|
| Lung | 1 | 2014 | 946 | 0.070 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2008 | 5 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 21 | 0.070 |
Why?
|
| Neurilemmoma | 1 | 2008 | 11 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2008 | 13 | 0.070 |
Why?
|
| Inflammation | 2 | 2006 | 1145 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2008 | 67 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 203 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1082 | 0.070 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 32 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2013 | 2151 | 0.070 |
Why?
|
| Scalp | 1 | 2007 | 29 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2010 | 625 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 863 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 148 | 0.060 |
Why?
|
| Lymphedema | 1 | 2006 | 7 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 94 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 74 | 0.060 |
Why?
|
| Dermatitis | 1 | 2006 | 28 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2004 | 183 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 205 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2005 | 2 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 663 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 416 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 168 | 0.060 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2005 | 10 | 0.060 |
Why?
|
| Gene Expression | 3 | 2013 | 839 | 0.060 |
Why?
|
| Organ Size | 2 | 2006 | 172 | 0.060 |
Why?
|
| Mucins | 1 | 2005 | 26 | 0.060 |
Why?
|
| Scleral Diseases | 1 | 2004 | 1 | 0.050 |
Why?
|
| Orbital Neoplasms | 1 | 2004 | 6 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 233 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2004 | 17 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2003 | 6 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 54 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 21 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2003 | 62 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2016 | 189 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2025 | 350 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2003 | 581 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 1616 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2005 | 608 | 0.050 |
Why?
|
| Peroxisome Proliferators | 1 | 2001 | 1 | 0.040 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2001 | 2 | 0.040 |
Why?
|
| Finasteride | 1 | 2001 | 5 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2001 | 33 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 142 | 0.040 |
Why?
|
| Luciferases | 2 | 2006 | 107 | 0.040 |
Why?
|
| Transfection | 2 | 2005 | 692 | 0.040 |
Why?
|
| Testis | 1 | 2001 | 149 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 308 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 701 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 619 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 1306 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1347 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 860 | 0.040 |
Why?
|
| Erucic Acids | 1 | 1998 | 1 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1998 | 47 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 1 | 1998 | 27 | 0.040 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 1998 | 17 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 1998 | 19 | 0.040 |
Why?
|
| Vibrissae | 1 | 2017 | 7 | 0.030 |
Why?
|
| DNA Primers | 1 | 1998 | 291 | 0.030 |
Why?
|
| Ranidae | 1 | 1996 | 3 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1275 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 10 | 0.030 |
Why?
|
| Elasticity | 1 | 2016 | 43 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 41 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 78 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 131 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 123 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 292 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2009 | 190 | 0.030 |
Why?
|
| Ethylnitrosourea | 1 | 2016 | 7 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 334 | 0.030 |
Why?
|
| Publications | 1 | 2016 | 29 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 382 | 0.030 |
Why?
|
| Data Mining | 1 | 2016 | 38 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 235 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 199 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 138 | 0.030 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2014 | 12 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 29 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2015 | 96 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 36 | 0.030 |
Why?
|
| 3-Hydroxyacyl CoA Dehydrogenases | 1 | 1994 | 3 | 0.030 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 1994 | 2 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 447 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 128 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 676 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2014 | 232 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1994 | 255 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1592 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 158 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 525 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 413 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 491 | 0.030 |
Why?
|
| Genome | 1 | 2015 | 276 | 0.030 |
Why?
|
| Time Factors | 1 | 2001 | 3763 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 25 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 96 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 469 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 181 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2013 | 181 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 574 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2011 | 64 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 69 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 287 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 661 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 211 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 141 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 777 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 45 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 129 | 0.020 |
Why?
|
| Hypertelorism | 1 | 2009 | 1 | 0.020 |
Why?
|
| Retrognathia | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2571 | 0.020 |
Why?
|
| Collagen Type VII | 1 | 2009 | 5 | 0.020 |
Why?
|
| Palate | 1 | 2009 | 8 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2009 | 63 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 935 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 250 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 57 | 0.020 |
Why?
|
| Neurofibroma | 1 | 2008 | 3 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2008 | 8 | 0.020 |
Why?
|
| Adenoma | 1 | 2008 | 69 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 37 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 319 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 675 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2003 | 881 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 671 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2009 | 183 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2006 | 21 | 0.020 |
Why?
|
| Lymphoscintigraphy | 1 | 2006 | 6 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 2006 | 19 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2569 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 37 | 0.020 |
Why?
|
| Microspheres | 1 | 2006 | 56 | 0.020 |
Why?
|
| Granulocytes | 1 | 2006 | 71 | 0.020 |
Why?
|
| Complement Activation | 1 | 2006 | 47 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 185 | 0.020 |
Why?
|
| Fibrosis | 1 | 2006 | 160 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2006 | 135 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1120 | 0.010 |
Why?
|
| Granulosa Cell Tumor | 1 | 2005 | 5 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 2005 | 16 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2006 | 268 | 0.010 |
Why?
|
| Wound Healing | 1 | 2006 | 189 | 0.010 |
Why?
|
| Spleen | 1 | 2006 | 483 | 0.010 |
Why?
|
| Epithelium | 1 | 2005 | 96 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 1356 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 100 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 297 | 0.010 |
Why?
|
| Orbit Evisceration | 1 | 2004 | 2 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 451 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 489 | 0.010 |
Why?
|
| Biomarkers | 1 | 2008 | 1397 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 878 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 212 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 447 | 0.010 |
Why?
|
| Mutation | 1 | 2009 | 2607 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 1171 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5664 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2167 | 0.010 |
Why?
|
| Clofibric Acid | 1 | 1994 | 1 | 0.010 |
Why?
|
| Nafenopin | 1 | 1994 | 1 | 0.010 |
Why?
|
| Fibric Acids | 1 | 1994 | 2 | 0.010 |
Why?
|
| Diethylhexyl Phthalate | 1 | 1994 | 4 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1994 | 84 | 0.010 |
Why?
|
| Pyrimidines | 1 | 1994 | 137 | 0.010 |
Why?
|